Cardiovascular Drugs and Therapy
ISSN 0920-3206 · Springer Science+Business Media · United States · active 1969–2026
Metrics
“Cites per paper” is a two-year cited-by rate computed from OpenAlex. It is not a Clarivate Journal Impact Factor — we neither compute nor license that metric. Citation rates differ enormously between fields, so compare within a discipline.
Indexing & access
Access status: unknown. Where this comes from publisher-level signals rather than works-level data it is a heuristic — confirm on the journal’s own site, especially regarding any article processing charge.
Scope
Frequently asked
Is Cardiovascular Drugs and Therapy a predatory journal?
Our screening does not flag Cardiovascular Drugs and Therapy. That is not a guarantee of quality — it means the venue is not on Beall's archive (frozen since 2017) and does not match our name-pattern heuristic. It is listed in Scopus, Web of Science, PubMed, which is a positive signal.
Is Cardiovascular Drugs and Therapy indexed in Scopus or Web of Science?
Per our venue index, Cardiovascular Drugs and Therapy appears in: Scopus, Web of Science, PubMed. Index membership changes over time — confirm on the index's own site before relying on it.
What is Cardiovascular Drugs and Therapy's impact?
Papers in Cardiovascular Drugs and Therapy are cited about 2.6 times each within two years of publication, and Scimago places it in Q1, with an h-index of 98. This is not a Clarivate Journal Impact Factor — we neither compute nor license that metric — and a citation rate is a property of a field as much as of a journal.
Is Cardiovascular Drugs and Therapy open access?
We hold no reliable open-access classification for Cardiovascular Drugs and Therapy. Check the journal's own site for its access model and any article processing charge.
Similar venues
- Nature Reviews CardiologyQ1 · Nature Portfolio
- Journal of Biomedical ScienceQ1 · BioMed Central
- Basic Research in CardiologyQ1 · Springer Nature
- JAMA CardiologyQ1 · American Medical Association
- Seminars in Nuclear MedicineQ1 · Elsevier BV
- Current Atherosclerosis ReportsQ1 · Springer Science+Business Media